Investing in women’s health can increase global GDP (WEF)

Mexico City /

Improving women’s health and well-being is key to closing the gender gap, along with reproductive and maternal health. According to specialists, achieving equality between men and women in all areas will increase the world’s Gross Domestic Product (GDP) by up to $28 billion.

“Gender inequality is not only a pressing moral and social problem, but also a crucial economic challenge. If women, who make up half of the world’s working-age population, do not reach their full economic potential, the global economy will suffer,” said experts at consultancy McKinsey.

According to the World Economic Forum (WEF) with the strategies that are currently applied, closing the gender gap could take up to 132 years, Therefore, it is necessary to seek solutions that promote women’s health.

“Not only is it a moral necessity, but addressing women’s health needs and improving gender equality is smart across the board, for individual, societal and economic prosperity,” the WEF said.

A woman’s health lays the foundation for the health of her children, her family, her community and generations to come.

Laboratories Against Women

Based on a report from UKcalled Healthy Mom, Healthy Baby, Healthy Future (Healthy Mom, Healthy Baby, Healthy Future), the WEF highlights the “great lack of research activity” in medicines for women, noting that only two new drugs have been approved for use in pregnancy in the past 40 last years.

“This lack of up-to-date information leaves pregnant women and their doctors in the dark about whether to continue certain medications during pregnancy,” they commented.

The lack of priority given to women’s health and reproductive biology as scientific fields is systemic, as they pointed out that since the thalidomide tragedy in 1950s and until 1993, the US government’s Food and Drug Administration recommended excluding women of childbearing age from phase I and early phase II clinical trials.

“We carry this bias with us in research and clinical settings to this day. Women are consistently underrepresented in clinical trials, and many drugs used for female-specific conditions have never been tested in women in clinical trials.

They argued that women are not just “little men” and should be taken into account when designing clinical trials, taking into account the cellular and molecular differences between male and female bodies.

“After all, a woman’s health lays the foundation for the health of her children, her family, her community and generations to come,” they concluded.

CVD

.

Leave a Comment